Skip to main content

Global Allogeneic Cell Therapy Market to See 25% CAGR Expansion with New Innovations by 2030

 


The global allogeneic cell therapy market is set to witness a growth rate of 25% in the next 5 years. Growing demand for off-the-shelf therapies; advancements in cell engineering and genomic technologies; rising prevalence of chronic and rare diseases; and strong pipeline and clinical trials are some of the key factors driving the allogeneic cell therapy market.

Allogeneic cell therapy involves administering cells from a healthy donor to a patient to treat various medical conditions. Unlike autologous therapies, which use patient's own cells, allogeneic treatments utilize donor cells, enabling the creation of off-the-shelf products that can be readily available for multiple patients. This approach is particularly beneficial in treating diseases such as leukemia, lymphoma, and other blood disorders, where the donor's healthy cells can replace the patient's damaged or diseased cells, promoting recovery and restoring normal function.

Download a free sample report for in-depth market insights

https://meditechinsights.com/allogeneic-cell-therapy-market/request-sample/

Growing demand for off-the-shelf therapies to propel market demand

The growing demand for off-the-shelf therapies is a significant driver in the allogeneic cell therapy market. Unlike autologous therapies, which require cells to be sourced and processed from each individual patient, allogeneic cell therapies utilize cells from a single donor to treat multiple patients. This approach reduces production time, lowers costs, and simplifies logistics, making treatments more accessible and scalable. Additionally, the rise in chronic diseases and the need for rapid, cost-effective therapeutic solutions are further boosting the adoption of off-the-shelf therapies, positioning allogeneic cell therapies as a promising and efficient option for addressing unmet medical needs.

Advancements in cell engineering and genomic technologies is driving the market growth

Advancements in cell engineering and genomic technologies are propelling the allogeneic cell therapy market by enabling the development of safer, more effective therapies. Cutting-edge techniques like CRISPR and TALEN allow precise genetic modifications, reducing the risk of immune rejection and enhancing cell functionality. These technologies also improve the scalability and consistency of cell production, ensuring high-quality, off-the-shelf therapies. Furthermore, breakthroughs in immune evasion strategies and enhanced cell viability boost therapeutic potential in various diseases. As a result, innovations in cell and genomic engineering are accelerating clinical development and expanding the application scope of allogeneic cell therapies, driving market growth.

Competitive Landscape Analysis

The global allogeneic cell therapy market is marked by the presence of established and emerging market players such as Athersys, Inc., Mesoblast Ltd, BioRestorative Therapies, Inc., Poseida Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Fate Therapeutics, Allogene Therapeutics, Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., and CRISPR Therapeutics; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Unlock key data with a sample report for competitive analysis:

https://meditechinsights.com/allogeneic-cell-therapy-market/request-sample/

Global Allogeneic Cell Therapy Market Segmentation

This report by Medi-Tech Insights provides the size of the global allogeneic cell therapy market at the regional- and country-level from 2023 to 2030. The report further segments the market based on source, and application.

Market Size & Forecast (2023-2030), By Source, USD Million

  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies (HSCs)
    • Mesenchymal Stem Cell Therapies (MSCs)
    • Other Stem Cell Therapies
  • Non-stem Cell Therapies
    • T-Cell Therapies
    • Natural Killer (NK) Cell Therapies
    • Other Non-stem Cell Therapies
  • Others

Market Size & Forecast (2023-2030), By Application, USD Million

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Autoimmune Diseases
  • Orthopaedic Disorders
  • Haematological Disorders
  • Others

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more